Abeona Therapeutics (ABEO) Net Cash Flow (2011 - 2026)

Abeona Therapeutics' Net Cash Flow history runs 16 years deep, the most recent figure standing at -$17.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 129.93% year-over-year to -$17.1 million; the TTM figure through Mar 2026 stood at $45.1 million (up 2880.52% YoY), while the FY2025 annual figure was $54.7 million, up 516.19% from the prior year.
• Net Cash Flow was -$17.1 million for Q1 2026 at Abeona Therapeutics, down from -$4.8 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $147.6 million in Q2 2025 to a low of -$80.7 million in Q3 2025.
• Historically, Net Cash Flow has averaged $1.5 million across 5 years, with a median of -$1.5 million in 2023.
• Biggest YoY gain for Net Cash Flow was 991.78% in 2024; the steepest drop was 1135.96% in 2024.
• A 5-year view of Net Cash Flow shows it stood at $3.5 million in 2022, then soared by 180.17% to $9.8 million in 2023, then fell by 21.82% to $7.6 million in 2024, then plunged by 162.7% to -$4.8 million in 2025, then slumped by 256.59% to -$17.1 million in 2026.
• The last three Net Cash Flow figures came in at -$17.1 million (Q1 2026), -$4.8 million (Q4 2025), and -$80.7 million (Q3 2025), per Business Quant data.